Sign in
Taking peoplePhase 1

CAR-T cells aimed at BCMA and CD70 for drug-resistant nephrotic syndrome

Tests anti-BCMA/CD70 CAR-T cells in people with multi-drug resistant nephrotic syndrome.

Key facts

Who runs it
The Children's Hospital of Zhejiang University School of Medicine
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS
Status
Recruiting
Phase
Phase 1
People taking part
18 people, planned
Started
13 Aug 2024
Expected to end
31 Jul 2027
Type of study
Interventional
Treatments tested
  • anti-BCMA/CD70 CAR-T cells
Record updated
29 August 2025

Who can take part

The trial is looking for people with steroid-resistant nephrotic syndrome (SRNS) that has not responded to several drugs. They will receive anti-BCMA/CD70 CAR-T cells.

Age
2 years and older.
Sex
All sexes can join.
Disease stage
SRNS diagnosed by the 2021 KDIGO guidelines. A kidney biopsy must show minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS). Kidney function must be eGFR ≥30 mL/min/1.73m2. Heart, liver and lung function must be mostly normal.
Earlier treatment
No complete response after 12 months of two standard-dose drugs that work in different ways, or the disease came back after remission. At least one drug must be a calcineurin inhibitor such as cyclosporine or tacrolimus. People with no remission after 3 to 6 months of one calcineurin inhibitor may also join if the researcher agrees. People who had CAR-T or other gene-modified cell therapy before cannot join.
Main reasons for not taking part
  • Kidney disease that genetic tests show is inherited, or a biopsy showing IgA nephropathy, membranous nephropathy or membranoproliferative glomerulonephritis.
  • Dialysis or other kidney replacement therapy within 3 months before the infusion.
  • Solid organ or stem cell transplant within 3 months before screening.
  • Active hepatitis B or C, HIV, syphilis or CMV infection.
  • Cancer, serious heart disease, or stroke or seizure within 6 months.
Show the full registry criteria (22)Hide the full registry criteria

Who can take part

  • 1. Age ≥2 years old, gender unlimited
  • 2.Diagnosed with SRNS according to the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guidelines and have not achieved a complete response after 12 months of treatment with two standard doses of hormone replacement drugs with different mechanisms of action or relapse of disease activity after remission (at least one of the two drugs is a calcineurin inhibitor such as cyclosporine or tacrolimus; Other hormone replacement drugs include Mycophenolate Mofetil, cyclophosphamide, Taitacept or rituximab); Or if no remission has been achieved after 3 to 6 months of adequate treatment with one calcineurin inhibitor, if the researcher judges that the benefits outweigh the risks and the patient or guardian has fully informed consent, the patient can be considered for inclusion.Patients with other diseases, such as systemic lupus erythematosus, requiring long-term systemic treatment with glucocorticoids or immunosuppressants, may be considered for inclusion after the investigator determines that the benefits outweigh the risks and the patient or guardian has fully informed consent
  • 3. Renal biopsy was performed and the pathological type was determined to be minimal lesion nephropathy(MCD) or focal segmental glomerulosclerosis (FSGS)
  • 4. The functions of important organs are basically normal: Cardiac function: Left ventricular ejection fraction (LVEF) ≥55% with no obvious abnormality in electrocardiogram; Renal function: eGFR≥30ML/min/1.73m2# Liver function: Asparagus cochinchinensis transaseminase (AST) and Alanine Aminotransferase (ALT)≤3.0 upper limit of normal, Total Bilirubin (TBIL) in serum ≤2.0×upper limit of normal; Lung function: No serious lung lesions, SpO2≥92%
  • 5. Met the standards of leukapheresis or intravenous blood collection, No contraindication for cell collection
  • 6. Negative pregnancy test for female Subjects of childbearing age, agree to take effective contraceptive measures the first year after CAR-T infusion
  • 7. Participants or their guardians agrees to participate in the clinical trial and sign the informed consent form which indicating that he/she understands the purpose and procedure of the clinical trial and is willing to participate in the study

Who cannot take part

  • 1. Received CAR T cell therapy or other gene-modified cell therapy previously
  • 5. Renal replacement therapy has been or is being performed within 3 months prior to transfusion. (if acute kidney injury factors were considered, patients with chronic kidney disease were excluded, and the benefits outweighed the risks as determined by the investigator and with the full and informed consent of the patient or guardian could be considered for inclusion)
  • 6. Renal replacement therapy has been or is being performed within 3 months prior to transfusion
  • 7. Have a history of congenital heart disease or acute myocardial infarction within 6 months prior to screening; Or severe arrhythmias (including multisource frequent supraventricular tachycardia, ventricular tachycardia, etc.); Or combined with moderate to massive pericardial effusion, serious myocarditis, etc; Or patients with unstable vital signs who need hypertensive drugs
  • 8. Received solid organ transplantation or hematopoietic stem cell transplantation within 3 months prior to screening; Acute graft-versus-host disease (GVHD) of grade 2 or above was present within 2 weeks prior to screening
  • 10. Macrophage activation syndrome occurred within 1 month prior to screening
  • 11. Received live vaccine within 4 weeks before screening
  • 14. Patients who participated in other clinical study within 1 months prior to enrollment
  • 2. Patients had a cerebrovascular accident or seizure, or other active central nervous system disease within 6 months
  • 3. Genetic tests have confirmed hereditary kidney disease
  • 9. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal reference value range; Or hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA titer greater than the normal reference value range; Or positive for human immunodeficiency virus (HIV) antibodies; Or syphilis test positive; Or cytomegalovirus (CMV) DNA test positive
  • 12. Patients with malignant diseases such as tumors before screening, or with other serious life-threatening diseases
  • 15. Any other conditions that the investigators deem it unsuitable for the study
  • 4. Renal biopsy has been confirmed as immunoglobulin A nephropathy, idiopathic membranous nephropathy or membranoproliferative glomerulonephritis
  • 13. Tested positive in Blood pregnancy test

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Multi-drug resistant nephrotic syndrome or CAR-T cell therapy

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an investigator-initiated trial aimed at assessing the safety and efficacy of anti-BCMA/CD70 CAR-T cells in the treatment of patients with Multi-drug resistant SRNS

The group in the trial

  • CAR-T treatment groupTreatment being tested

    The trial consists of two phases, Dose Exploration(Part A) and Dose Expansion (Part B). In Part A, three dose groups (0.3×105/kg, 1×105/kg, 3×105/kg) are set up, starting from the low dose group to explore the safe and effective dose. Each dose group will be enrolled in 3 cases.If the optimal effective dose is still not explored in the highest dose group, the dose can be increased according to the situation, and the highest dose is no more than 6×105/kg. Upon the completion of Part A, 1 optimal dose is selected by the comprehensive judgment of the investigator and the technical partner to enter into the Part B stage. The group will then be enrolled in 3\~6 cases to continue to validate the safety and efficacy.A total enrollment of 12-18 patients is expected in the whole process of the trial.

    Treatment: anti-BCMA/CD70 CAR-T cells

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Study of Therapeutic Efficacy of Anti-B Cell Maturation Antigen(BCMA)/Cluster of Differentiation 70(CD70 )CAR-T Cells in Patients With Multi-drug Resistant SRNS
Plain-language title
CAR-T cells aimed at BCMA and CD70 for drug-resistant nephrotic syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06553898, who can take part
Record updated
29 August 2025